Report No. 32/2026 Conclusion of a Material Agreement for the Construction of a Steel Structure as Part of the Development of a New Pharmaceutical Manufacturing Facility

_MACHINE TRANSLATION_ The Management Board of Bioceltix S.A. with its registered office in Wrocław (the “Issuer” or the “Company”), with reference to ESPI Current Report No. 16/2025 dated 16 July 2025 concerning the execution of a grant agreement for the project entitled “Construction and Launch of a Pharmaceutical Manufacturing Facility for Innovative Advanced Therapy Veterinary […]

Report No. 31/2026 Management Board’s Assessment of the List of Questions Received from the European Medicines Agency and Timeline for Further Activities in the BCX-CM-J Registration Process Przekaż swoją opinię na temat programu BizChat

_MACHINE TRANSLATION_ The Management Board of Bioceltix S.A. with its registered office in Wrocław (the “Issuer” or the “Company”), with reference to ESPI Current Report No. 28/2026 dated 16 July 2026 regarding the receipt from the European Medicines Agency (“EMA”) of a list of questions as part of the process of seeking a positive recommendation […]

Report No. 30/2026 Registration of Amendments to the Articles of Association

_MACHINE TRANSLATION_ The Management Board of Bioceltix S.A. with its registered office in Wrocław (the “Issuer” or the “Company”) hereby informs that on 29 July 2026 it became aware that on 24 July 2026 the District Court for Wrocław-Fabryczna in Wrocław, 6th Commercial Division of the National Court Register, registered amendments to the Company’s Articles […]

Report No. 29/2026 Receipt of the Certificate Confirming the Finality of the Building Permit Decision for the “Manufacturing Facility for Biological Veterinary Medicinal Products” Project

_MACHINE TRANSLATION_ The Management Board of Bioceltix S.A. with its registered office in Wrocław (the “Company” or the “Issuer”), with reference to ESPI Current Report No. 14/2026 dated 9 June 2026 regarding the receipt of a building permit decision for the project entitled “Manufacturing Facility for Biological Veterinary Medicinal Products” (the “Project”), hereby informs that […]

Report No. 25/2026 CORR – Correction of Current Report No. 25/2026

_MACHINE TRANSLATION_ The Management Board of Bioceltix S.A. with its registered office in Wrocław (the “Issuer” or the “Company”), with reference to Current Report No. 25/2026 dated 15 July 2026, hereby informs that due to the inclusion in the report of an additional attachment No. 3 containing the Updated Proxy Voting Form in .docx format, […]

Report No. 28/2026 Receipt of the EMA List of Questions in the Process of Seeking a Positive Recommendation for the Marketing Authorisation of the Veterinary Medicinal Product BCX-CM-J

_MACHINE TRANSLATION_ The Management Board of Bioceltix S.A. with its registered office in Wrocław (the “Issuer” or the “Company”), with reference to ESPI Current Report No. 24/2026 dated 15 July 2026, hereby informs that on 16 July 2026 the Company received from the European Medicines Agency (the “EMA”) a list of questions regarding BCX-CM-J, a […]

Report No. 26/2026 List of Shareholders Holding at Least 5% of the Total Number of Votes at the Ordinary General Meeting of Shareholders Following the Resumption of the Meeting on 16 July 2026

_MACHINE TRANSLATION_ The Management Board of Bioceltix S.A. with its registered office in Wrocław (the “Issuer” or the “Company”) hereby publishes the list of shareholders who, at the Ordinary General Meeting of Shareholders of the Issuer (the “OGM”) held on 16 July 2026 and continued following adjournments announced on 23 June 2026 and 7 July […]

Report No. 25/2026 Submission of Draft Resolutions for the Ordinary General Meeting of Shareholders Przekaż swoją opinię na temat programu BizChat

_MACHINE TRANSLATION_ The Management Board of Bioceltix S.A. with its registered office in Wrocław (the “Issuer” or the “Company”) hereby announces that it has received from a shareholder representing at least one-twentieth of the Company’s share capital, namely TOTAL Closed-End Investment Fund (TOTAL Fundusz Inwestycyjny Zamknięty), a submission of draft resolutions pursuant to Article 401 […]

Report No. 24/2026 Update on the timeline for receiving the final list of questions from the EMA in the process of obtaining a positive recommendation for the marketing authorisation of the veterinary medicinal product BCX-CM-J.

_MACHINE TRANSLATION_ The Management Board of Bioceltix S.A. with its registered office in Wrocław (the “Issuer” or the “Company”), with reference to ESPI Current Report No. 11/2026 dated 14 May 2026, in which the Issuer informed about receiving confirmation of the submission to the European Medicines Agency (the “EMA”) of documentation containing explanations and responses […]

Report No. 23/2026 Resolutions adopted by the Ordinary General Meeting of Shareholders on 7 July 2026, together with information on the adjournment of the meeting until 16 July 2026 at 10:30 a.m.

_MACHINE TRANSLATION_ The Management Board of Bioceltix S.A. with its registered office in Wrocław (the “Issuer”, the “Company”) hereby publishes, as an attachment to this current report, the resolutions adopted by the Ordinary General Meeting of Shareholders (the “OGM”), which was resumed on 7 July 2026 following the adjournment announced on 23 June 2026, together […]

Report No. 22/2026 List of Shareholders Holding at Least 5% of the Total Voting Rights at the Ordinary General Meeting Following the Resumption of Proceedings on 7 July 2026 Until the Announcement of a Recess in the Meeting

_MACHINE TRANSLATION_ The Management Board of Bioceltix S.A. with its registered office in Wrocław (the “Issuer” or the “Company”) hereby provides the list of shareholders who, at the Ordinary General Meeting of the Issuer (the “OGM”), held on 7 July 2026 and continued following the recess announced on 23 June 2026 until the announcement of […]

Bioceltix Enters into Grant Agreement for a Cell-Free Therapy Project for Dogs in Consortium with Jagiellonian University

Bioceltix S.A. has signed a grant agreement for the “InnoBioVet” project under the European Funds for a Modern Economy (FENG) programme. The project will be carried out in a consortium with researchers from Jagiellonian University. A Global Market Seeking New Solutions The veterinary healthcare market is growing rapidly, and spending on companion animal care continues […]

Report No. 21/2026 Appointment of a Member of the Supervisory Board – Supplement to the Current Report

_MACHINE TRANSLATION_ The Management Board of Bioceltix S.A. with its registered office in Wrocław (the “Issuer” or the “Company”), with reference to ESPI Current Report No. 19/2026 dated 23 June 2026, hereby provides, as an attachment, information concerning Mr. Szymon Ruta, newly appointed Member of the Supervisory Board. Attachments: Curriculum Vitae of the Supervisory Board […]

Report No. 20/2026 Execution of a Funding Agreement with the National Centre for Research and Development for the Project “Innovative Cell-Free Biological Medicinal Product for Veterinary Applications (InnoBioVet)” under the European Funds for a Modern Economy Programme

_MACHINE TRANSLATION_ Execution of a Funding Agreement with the National Centre for Research and Development for the Project “Innovative Cell-Free Biological Medicinal Product for Veterinary Applications (InnoBioVet)” under the European Funds for a Modern Economy Programme The Management Board of Bioceltix S.A. with its registered office in Wrocław (the “Issuer” or the “Company”), with reference […]

Report No. 19/2026 Appointment of a Member of the Supervisory Board

_MACHINE TRANSLATION_ The Management Board of Bioceltix S.A., with its registered office in Wrocław (the “Issuer”, the “Company”), hereby announces that the Ordinary General Meeting of the Company held today, i.e., on 23 June 2026, by virtue of Resolution No. 18/06/2026 on the appointment of a Member of the Supervisory Board, appointed Mr. Szymon Ruta […]

Report No. 18/2026 Content of the resolutions adopted during the Ordinary General Meeting held on 23 June 2026, together with information on the announcement of a break in the proceedings until 7 July 2026 at 13:30

_MACHINE TRANSLATION_ The Management Board of Bioceltix S.A., with its registered office in Wrocław (the “Issuer”, the “Company”), hereby provides, as an attachment to this current report, the content of the resolutions adopted by the Ordinary General Meeting (the “OGM”) held on 23 June 2026, together with the voting results. During the OGM, no items […]

Report No. 17/2026 List of shareholders holding at least 5% of votes at the Ordinary General Meeting on 23 June 2026 until the announcement of the break in the proceedings.

_MACHINE TRANSLATION_ The Management Board of Bioceltix S.A., with its registered office in Wrocław (the “Issuer”, the “Company”), hereby provides the list of shareholders who, at the Ordinary General Meeting of the Issuer (the “OGM”) held on 23 June 2026, until the announcement of a break in the proceedings, held at least 5% of the […]

Report No. 16/2026 Resignation of a Member of the Supervisory Board

_MACHINE TRANSLATION_ The Management Board of Bioceltix S.A., with its registered office in Wrocław (the “Issuer”, the “Company”), hereby informs that on 23 June 2026 it received a statement from Mr. Piotr Lembas regarding his resignation from the position of Member of the Supervisory Board of the Company and from the position of Chairman of […]

Report No. 14/2026 Receipt of the building permit decision for the investment project titled ‘Manufacturing Plant for Biological Veterinary Medicines’

_MACHINE TRANSLATION_ The Management Board of Bioceltix S.A., with its registered office in Wrocław (the “Company”, the “Issuer”), with reference to Current Report ESPI No. 7/2026 of 9 March 2026 regarding the submission of an application for a building permit for the investment project titled “Manufacturing Plant for Biological Veterinary Medicines” (the “Investment”), hereby informs […]

Responses to the EMA, Grant Funding, and Industry Networking

Dear Sir or Madam, A lot has been happening at Bioceltix recently. We are engaged in a constructive dialogue with the European Medicines Agency, sharing the Bioceltix story at key industry events, and gratefully receiving further important recognitions. We have been visiting Kraków, Bruges, the WallStreet Conference in Karpacz, and EquiMental in Warsaw. Each of […]

Report No. 15/2026 Nomination of a candidate for a Member of the Supervisory Board

_MACHINE TRANSLATION_ The Management Board of Bioceltix S.A., with its registered office in Wrocław (the “Issuer”, the “Company”), with reference to Current Report No. 12/2026 of 26 May 2026 concerning the convening of the Ordinary General Meeting for 23 June 2026, and Current Report No. 13/2026 of 2 June 2026 concerning amendments to the agenda […]

Report No. 13/2026 Information on introducing changes to the agenda of the Ordinary General Meeting at the request of a shareholder of the Company

_MACHINE TRANSLATION_ The Management Board of Bioceltix S.A., with its registered office in Wrocław (the “Company” or the “Issuer”), announces that today (i.e. on 2 June 2026) the Company received information on the submission of a request by a shareholder representing at least one-twentieth of the share capital, i.e. Towarzystwo Funduszy Inwestycyjnych PZU S.A. with […]

Ordinary General Meeting convened for 23 June 2026

_MACHINE TRANSLATION_ The Management Board of Bioceltix S.A., with its registered office in Wrocław (the “Issuer”, the “Company”), announces that the Ordinary General Meeting of the Issuer has been convened for 23 June 2026, to commence at 12:00 p.m. at the registered office of the Management Board of the Company, i.e. in Wrocław (51-317), at […]

Report No. 12/2026 Convening of the Annual General Meeting on 23 June 2026

_MACHINE TRANSLATION_ The Management Board of Bioceltix S.A., with its registered office in Wrocław (the “Issuer”, the “Company”), announces that the Ordinary General Meeting of the Issuer has been convened for 23 June 2026, to commence at 12:00 p.m. at the registered office of the Management Board of the Company, i.e. in Wrocław (51-317), at […]

Bioceltix is getting closer to the registration of BCX‑CM‑J for osteoarthritis in dogs. The dialogue with the European Medicines Agency enters the next phase

Bioceltix has announced that it has submitted responses to the European Medicines Agency (EMA) regarding questions related to the BCX‑CM‑J product. This is one of the key elements of the registration process preceding the marketing authorisation of the drug. BCX‑CM‑J, developed by the Wrocław‑based biotech company, has the potential to become the world’s first veterinary […]

NCBR: Bioceltix project selected for funding in the amount of over PLN 15 million

It is estimated that as many as 15% of dogs suffer from atopic dermatitis. This is a chronic and very troublesome disease that significantly affects the quality of life of both animals and their caregivers. At Bioceltix, we are working on a solution that can genuinely help change this. Our project focused on developing a […]

Report No. 11/2026 Submission to EMA of the responses to questions in the process of applying for a positive recommendation for the marketing authorization of the veterinary medicinal product BCX‑CM‑J

_MACHINE TRANSLATION_ The Management Board of Bioceltix S.A., with its registered office in Wrocław (the “Issuer”, the “Company”), with reference to Current Report ESPI No. 49/2025 of 5 December 2025, hereby informs that it has received confirmation that the Issuer’s attorney has submitted to the European Medicines Agency (“EMA”) the documentation containing all clarifications and […]

Report No. 10/2026 Information on the positive evaluation of the project titled: “Innovative Cell‑Free Biological Medicinal Product for Veterinary Applications (InnoBioVet)” under the European Funds for a Modern Economy programme

_MACHINE TRANSLATION_ Management Board of Bioceltix S.A., with its registered office in Wrocław (the “Issuer”, the “Company”), announces that on 29 April 2026 it received information on the positive evaluation of the project titled “Innovative Cell‑Free Biological Medicinal Product for Veterinary Applications (InnoBioVet)” (the “Project”), submitted by the Issuer for co‑financing under the call FENG.01.01‑IP.01‑002/25 […]

Report No. 9/2026 Conclusion of an advisory agreement regarding regulatory support in the U.S. market

_MACHINE TRANSLATION_ The Management Board of Bioceltix S.A. with its registered office in Wrocław (the “Company”, the “Issuer”) hereby announces that on April 13, 2026, it concluded an advisory agreement with a specialized advisory entity regarding support for the development process of the Company’s stem cell-based veterinary medicinal products in the U.S. market. The agreement […]

We are in the TOP3 of the “Stock Exchange Company of the Year”

We made our debut in the “Stock Exchange Company of the Year” ranking a year ago. Yesterday, we once again stood on the podium, adding four more distinctions to our pool of awards. In the 27th edition of the Puls Biznesu ranking, we received the highest scores from analysts and fund managers in the “Growth […]

Puls Biznesu: Bioceltix on the starting blocks for pharmaceutical millions

The 27th “Stock Exchange Company of the Year” gala, a competition organized by the editorial team of Puls Biznesu, is now behind us. Each year, the selection of the best of the best is made by 100 stock market analysts, investment advisors, and asset managers representing brokerage houses and offices, pension funds, and investment funds. […]

Report No. 8/2026 Results from long-term observation of patients in the clinical trial of the product BCX-CM-AD intended for the treatment of atopic dermatitis in dogs

_MACHINE TRANSLATION_ The Management Board of Bioceltix S.A. with its registered office in Wrocław (the “Issuer”, the “Company”), with reference to current report ESPI No. 19/2025 dated August 12, 2025 informing about the final results of the clinical trial regarding the safety and efficacy of the product BCX-CM-AD in the treatment of atopic dermatitis in […]

Important decisions, new research, networking

Good morning, Pet owners may have a brain that is biologically up to 15 years “younger” than that of people without a pet. This is suggested by findings from the Alabama Brain Study on Risk for Dementia. The analysis indicates that regular contact with a four-legged companion may be associated with better performance in cognitive […]

Report No. 7/2026 Submission of an application for a building permit for the investment project entitled “Manufacturing facility for biological veterinary medicinal products”

_MACHINE TRANSLATION_ The Management Board of Bioceltix S.A. with its registered office in Wrocław (the “Company”, the “Issuer”), with reference to current ESPI reports No. 4/2024 dated 7 May 2024, No. 39/2024 dated 17 December 2024 and No. 5/2026 dated 29 January 2026, hereby informs that on 9 March 2026 it became aware that on […]

Report No. 6/2026 Obtaining Information on the Issuance of a GMP Certificate for Bioceltix S.A.

_MACHINE TRANSLATION_ The Management Board of Bioceltix S.A. (the “Company”, the “Issuer”), with reference to current report ESPI No. 51/2025 dated 23 December 2025 regarding receipt of the final report from the Chief Pharmaceutical Inspector (Główny Inspektor Farmaceutyczny, “GIF”) confirming the Company’s compliance with Good Manufacturing Practice (“GMP”), hereby announces that on 17 February 2026 […]

Report No. 5/2026 Receipt of the decision on environmental conditions for the investment entitled “Biological Veterinary Medicinal Products Manufacturing Facility”

_MACHINE TRANSLATION_ The Management Board of Bioceltix S.A., with its registered office in Wrocław (the “Company”, the “Issuer”), with reference to ESPI current reports No. 4/2024 dated 7 May 2024 and No. 39/2024 dated 17 December 2024, hereby informs that on 29 January 2026 it received the decision on environmental conditions No. WSR-OS.6220.87.2024.AN dated 29 […]

Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.